Metabolic tumour volumes measured at staging in lymphoma: Methodological evaluation on phantom experiments and patients

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 6, 2014, Pages 1113-1122

  Meignan, Michel ^a,e   Sasanelli, Myriam ^a   Casasnovas, René Olivier ^b   Luminari, Stefano ^c   Fioroni, Federica ^d   Coriani, Chiara ^d   Masset, Helene ^e   Itti, Emmanuel ^a   Gobbi, Paolo G ^f   Merli, Francesco ^d   Versari, Annibale ^d  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b HÔPITAL DU BOCAGE   (France)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d S MARIA NUOVA HOSPITAL   (Italy)

^e HENRI MONDOR HOSPITAL   (France)

^f UNIVERSITY OF PAVIA   (Italy)

Author keywords

Lymphoma; Metabolic volume; PET CT; Prognosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HODGKIN DISEASE; HUMAN; IMAGING PHANTOM; LARGE CELL LYMPHOMA; MALE; ONCOLOGICAL PARAMETERS; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; QUALITY CONTROL; TOTAL METABOLIC TUMOR VOLUME; TUMOR GROWTH; ADOLESCENT; AGED; COMPUTER ASSISTED TOMOGRAPHY; DEVICES; DIAGNOSTIC USE; EVALUATION STUDY; IMAGE QUALITY; MIDDLE AGED; MULTIMODAL IMAGING; PATHOLOGY; SCINTISCANNING; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTIMODAL IMAGING; PHANTOMS, IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 84900807519     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2705-y     Document Type: Article

References (33)

1. Eichenauer DA, Engert A, Dreyling M. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22 Suppl 6:vi55-8.
2. Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, et al. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol. 2008;9:435-44.
3. Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013-22.
4. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease. N Engl J Med. 1998;339:1506-14.
5. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-42.
6. Gobbi PG, Bassi E, Bergonzi M, Merli F, Coriani C, Iannitto E, et al. Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy. Hematol Oncol. 2012;30:194-9.
7. Van de Wiele C, Kruse V, Smeets P, Sathekge M, Maes A. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging. 2012;40:290-301.
8. Berkowitz A, Basu S, Srinivas S, Sankaran S, Schuster S, Alavi A. Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET. Nucl Med Commun. 2008;29:521-6.
9. Song MK, Chung JS, Shin HJ, Moon JH, Lee JO, Lee HS, et al. Prognostic value of metabolic tumor volume on PET/CT in primary gastrointestinal diffuse large B cell lymphoma. Cancer Sci. 2012;103:477-82.
10. Song MK, Chung JS, Shin HJ, Lee SM, Lee SE, Lee HS, et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol. 2012;91:697-703.
11. Mikhaeel NG, Smith D, Philips MM, Dunn JT, Fields PA, Moller H, et al. Does quantitative PET-CT predict prognosis in diffuse large B cell lymphoma. Hematol Oncol. 2013;31 Suppl 1:96-150.
12. Song MK, Chung JS, Lee JJ, Jeong SY, Lee SM, Hong JS, et al. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma. Cancer Sci. 2013;104:1656-61.
13. Luminari S, Cesaretti M, Tomasello C, Guida A, Bagni B, Merli F, et al. Use of 2-[18 F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy. Leuk Lymphoma. 2011;52:1689-96.
14. Casasnovas RO, Meignan M, Berriolo-Riedinger A, Bardet S, Julian A, Thieblemont C, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118:37-43.
15. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571-8.
16. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181-200.
17. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989;45:255-68.
18. Barnhart HX, Haber MJ, Lin LI. An overview on assessing agreement with continuous measurements. J Biopharm Stat. 2007;17:529-69.
19. McBride GB. A proposal for strength of agreement criteria for Lin's concordance correlation coefficient. NIWA Client Report HAM2005-062. Hamilton, New Zealand: National Institute of Water & Atmospheric Research Ltd; 2005.
20. Erdi YE, Mawlawi O, Larson SM, Imbriaco M, Yeung H, Finn R, et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer. 1997;80:2505-9.
21. Ford EC, Kinahan PE, Hanlon L, Alessio A, Rajendran J, Schwartz DL, et al. Tumor delineation using PET in head and neck cancers: threshold contouring and lesion volumes. Med Phys. 2006;33:4280-8.
22. van Dalen JA, Hoffmann AL, Dicken V, Vogel WV, Wiering B, Ruers TJ, et al. A novel iterative method for lesion delineation and volumetric quantification with FDG PET. Nucl Med Commun. 2007;28:485-93.
23. Schinagl DA, Vogel WV, Hoffmann AL, van Dalen JA, Oyen WJ, Kaanders JH. Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69:1282-9.
24. Frings V, de Langen AJ, Smit EF, van Velden FH, Hoekstra OS, van Tinteren H, et al. Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer. J Nucl Med. 2010;51:1870-7.
25. Sasanelli M, Itti E, Biggi A, Berriolo-Riedinger A, Cashen A, Tilly H, et al. Prognostic value of pretherapy metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in patients with diffuse large B-cell lymphoma (DLBCL). J Nucl Med. 2012;53:170P.
26. Casasnovas RO, Sasanelli M, Berriolo-Riedinger A, Morschhauser F, Itti E, Huglo D, et al. Baseline metabolic tumor volume is predictive of patient outcome in diffuse large B cell lymphoma. Blood. 2012;120:1598.
27. Bodet-Milin C, Kraeber-Bodere F, Moreau P, Campion L, Dupas B, Le Gouill S. Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma. Haematologica. 2008;93:471-2.
28. Schöder H, Noy A, Gönen M, Weng L, Green D, Erdi YE, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2005;23:4643-51.
29. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S-50S.
30. Kanoun SRC, Berriolo-Riedinger A, Humbert O, Dygay-Cochet I, Chretien ML, Legouge C, et al. Metabolic tumor volume is an independent prognosis factor predicting patient's outcome in Hodgkin lymphoma. Blood. 2012;120:3631.
31. Nestle U, Kremp S, Schaefer-Schuler A, Sebastian-Welsch C, Hellwig D, Rübe C, et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med. 2005;46:1342-8.
32. Jentzen W, Freudenberg L, Eising EG, Heinze M, Brandau W, Bockisch A. Segmentation of PET volumes by iterative image thresholding. J Nucl Med. 2007;48:108-14.
33. Tylski P, Stute S, Grotus N, Doyeux K, Hapdey S, Gardin I, et al. Comparative assessment of methods for estimating tumor volume and standardized uptake value in (18)F-FDG PET. J Nucl Med. 2010;51:268-76.